Adaptive upregulation of EGFR limits attenuation of tumor growth by neutralizing IL6 antibodies, with implications for combined therapy in ovarian cancer

Cancer Research

Volumn 75, Issue 7, 2015, Pages 1255-1264

  Milagre, Carla S ^a   Gopinathan, Ganga ^a   Everitt, Gemma ^a   Thompson, Richard G ^a   Kulbe, Hagen ^a   Zhong, Haihong ^b   Hollingsworth, Robert E ^b   Grose, Richard ^a   Bowtell, David D L ^c   Hochhauser, Daniel ^d   Balkwill, Frances R ^a  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b MEDIMMUNE   (United States)

^c PETER MACCALLUM CANCER CENTRE   (Australia)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; GEFITINIB; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; KARYOPHERIN BETA; MITOGEN ACTIVATED PROTEIN KINASE; STAT3 PROTEIN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN; IL6 PROTEIN, HUMAN; NEUTRALIZING ANTIBODY; QUINAZOLINE DERIVATIVE; STAT3 PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME PHOSPHORYLATION; FEMALE; HUMAN; HUMAN CELL; INTRACELLULAR SIGNALING; MOUSE; NONHUMAN; NUCLEAR LOCALIZATION SIGNAL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; TUMOR GROWTH; TUMOR VOLUME; UPREGULATION; ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; CELL NUCLEUS; DRUG POTENTIATION; DRUG SCREENING; GENETICS; IMMUNOLOGY; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PHYSIOLOGY; PROTEIN TRANSPORT; SIGNAL TRANSDUCTION;

ANIMALS; ANTIBODIES, NEUTRALIZING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL NUCLEUS; DRUG SYNERGISM; FEMALE; HUMANS; INTERLEUKIN-6; MAP KINASE SIGNALING SYSTEM; MICE, INBRED BALB C; MICE, NUDE; OVARIAN NEOPLASMS; PROTEIN TRANSPORT; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; STAT3 TRANSCRIPTION FACTOR; TUMOR BURDEN; UP-REGULATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84941653574     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-14-1801     Document Type: Article

References (38)

1. Koji Taniguchia MK. IL6 and related cytokines as the critical lynchpins between inflammation and cancer. Semin Immunol 2014;26:54-74.
2. He G, Dhar D, Nakagawa H, Font-Burgada J, Ogata H, Jiang Y, et al. Identification of liver cancer progenitors whose malignant progression depends on autocrine IL6 signaling. Cell 2013;155:384-96.
3. Coward J KH, Chakravarty P, Leader D, Vassileva V, Leinster DA, Thompson R, et al. Interleukin-6 as a therapeutic target in human ovarian cancer. Clin Cancer Res 2011;15:6083-96.
4. Kulbe H, Chakravarty P, Leinster DA, Charles KA, Kwong J, Thompson RG, et al. A dynamic inflammatory cytokine network in the human ovarian cancer microenvironment. Cancer Res 2012;72:66-75.
5. Anglesio MS, George J, Kulbe H, Friedlander M, Rischin D, Lemech C, et al. IL6-STAT3-HIF signaling and therapeutic response to the angiogenesis inhibitor sunitinib in ovarian clear cell cancer. Clin Cancer Res 2011;17:2538-48.
6. Stone RL, Nick AM, McNeish IA, Balkwill F, Han HD, Bottsford-Miller J, et al. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med 2012;366:610-8.
7. Kulbe H, Thompson R, Wilson JL, Robinson S, Hagemann T, Fatah R, et al. The inflammatory cytokine tumor necrosis factor-alpha generates an autocrine tumor-promoting network in epithelial ovarian cancer cells. Cancer Res 2007;67:585-92.
8. Kulbe H, Hagemann T, Szlosarek PW, Balkwill FR, Wilson JL. The inflammatory cytokine tumor necrosis factor-alpha regulates chemokine receptor expression on ovarian cancer cells. Cancer Res 2005;65:10355-62.
9. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nat Commun 2013;4:2126.
10. Gassmann M, Grenacher B, Rohde B, Vogel J. Quantifying Western blots: pitfalls of densitometry. Electrophoresis 2009;30:1845-55.
11. Benard J, Da Silva J, De Blois MC, Boyer P, Duvillard P, Chiric E, et al. Characterization of a human ovarian adenocarcinoma line, IGROV1, in tissue culture and in nude mice. Cancer Res 1985;45:4970-9.
12. Kandala PK, Wright SE, Srivastava SK. Blocking epidermal growth factor receptor activation by 3,3′-diindolylmethane suppresses ovarian tumor growth in vitro and in vivo. J Pharmacol Exp Ther 2012;341:24-32.
13. Colomiere M, Findlay J, Ackland L, Ahmed N. Epidermal growth factor-induced ovarian carcinoma cell migration is associated with JAK2/STAT3 signals and changes in the abundance and localization of alpha6beta1 integrin. Int J Biochem Cell Biol 2009;41:1034-45.
14. Sheng Q, Liu J. The therapeutic potential of targeting the EGFR family in epithelial ovarian cancer. Br J Cancer 2011;104:1241-5.
15. Erjala K, Sundvall M, Junttila TT, Zhang N, Savisalo M, Mali P, et al. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells. Clin Cancer Res 2006;12:4103-11.
16. Wu K, Chang Q, Lu Y, Qiu P, Chen B, Thakur C, et al. Gefitinib resistance resulted from STAT3-mediated Akt activation in lung cancer cells. Oncotarget 2013;4:2430-8.
17. Kenny HA KT, Yamada SD, Lengyel E. Use of a novel 3D culture model to elucidate the role of mesothelial cells, fibroblasts and extra-cellular matrices on adhesion and invasion of ovarian cancer cells to the omentum. Int J Cancer 2007;1:1463-72.
18. Xia W, Wei Y, Du Y, Liu J, Chang B, Yu YL, et al. Nuclear expression of epidermal growth factor receptor is a novel prognostic value in patients with ovarian cancer. Mol Carcinog 2009;48:610-7.
19. Wang YN, Lee HH, Lee HJ, Du Y, Yamaguchi H, Hung MC. Membrane-bound trafficking regulates nuclear transport of integral epidermal growth factor receptor (EGFR) and ErbB-2. J Biol Chem 2012;287:16869-79.
20. Li C, Iida M, Dunn EF, Ghia AJ, Wheeler DL. Nuclear EGFR contributes to acquired resistance to cetuximab. Oncogene 2009;28:3801-13.
21. Lo HW, Ali-Seyed M, Wu Y, Bartholomeusz G, Hsu SC, Hung MC. Nuclear-cytoplasmic transport of EGFR involves receptor endocytosis, importin beta1 and CRM1. J Cell Biochem 2006;98:1570-83.
22. Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2006;94:184-8.
23. Wei-Chien Huanga Y-JC, Mien-Chie Hunga. Implication of nuclear EGFR in the development of resistance to anticancer therapies. BioMedicine 2011;1:2-10.
24. Brand TM, Iida M, Li C, Wheeler DL. The nuclear epidermal growth factor receptor signaling network and its role in cancer. Discov Med 2011;12:419-32.
25. Lo HW, Hung MC. Nuclear EGFR signalling network in cancers: linking EGFR pathway to cell cycle progression, nitric oxide pathway and patient survival. Br J Cancer 2007;96:R16-20.
26. Yu H, Jove R. The STATs of cancer-new molecular targets come of age. Nat Rev Cancer 2004;4:97-105.
27. Scuto A, Kujawski M, Kowolik C, Krymskaya L, Wang L, Weiss LM, et al. STAT3 inhibition is a therapeutic strategy for ABC-like diffuse large B-cell lymphoma. Cancer Res 2011;71:3182-8.
28. Phesse TJ, Buchert M, Stuart E, Flanagan DJ, Faux M, Afshar-Sterle S, et al. Partial inhibition of gp130-Jak-Stat3 signaling prevents Wnt-beta-catenin-mediated intestinal tumor growth and regeneration. Sci Signal 2014;7:ra92.
29. Alberti C, Pinciroli P, Valeri B, Ferri R, Ditto A, Umezawa K, et al. Ligand-dependent EGFR activation induces the co-expression of IL6 and PAI-1 via the NFkB pathway in advanced-stage epithelial ovarian cancer. Oncogene 2012;31:4139-49.
30. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, et al. Mutations in the EGFR kinase domain mediate STAT3 activation via IL6 production in human lung adenocarcinomas. J Clin Invest 2007;117:3846-56.
31. Aaronson DS, Muller M, Neves SR, Chung WC, Jayaram G, Iyengar R, et al. An androgen-IL6-Stat3 autocrine loop re-routes EGF signal in prostate cancer cells. Mol Cell Endocrinol 2007;270:50-6.
32. Wang Y, van Boxel-Dezaire AH, Cheon H, Yang J, Stark GR. STAT3 activation in response to IL6 is prolonged by the binding of IL6 receptor to EGF receptor. Proc Natl Acad Sci U S A 2013;110:16975-80.
33. Domcke S, Sinha R, Levine DA, Sander C, Schultz N. Evaluating cell lines as tumour models by comparison of genomic profiles. Nature Commun 2013;4:2126.
34. Bashashati A, Ha G, Tone A, Ding J, Prentice LM, Roth A, et al. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling. J Pathol 2013;231:21-34.
35. Vaughan S, Coward JI, Bast RC Jr, Berchuck A, Berek JS, Brenton JD, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nat Rev Cancer 2011;11:719-25.
36. Berns EM, Bowtell DD. The changing view of high-grade serous ovarian cancer. Cancer Res 2012;72:2701-4.
37. Perets R, Wyant GA, Muto KW, Bijron JG, Poole BB, Chin KT, et al. Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models. Cancer Cell 2013;24:751-65.
38. Murphy M, Stordal B. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review. Drug Resist Updat 2011;14:177-90.